On a fall morning in East L.A. in 1974, Dolores Madrigal and her husband, Orencio, ate breakfast while listening to ranchera radio station KWKW when a news segment aired that would change her life.
The lack of therapies for nonalcoholic steatohepatitis, or NASH, is drawing many companies into the pursuit of a treatment for this fatty liver disease. Madrigal Pharmaceuticals is pushing to the ...
Just a few days ago, Madrigal Pharmaceuticals made history by winning FDA approval for its metabolic dysfunction-associated steatohepatitis (MASH) med Rezdiffra. Now that the launch is in sight, the ...
Madrigal Pharmaceuticals, Inc. recently received FDA approval for its lead candidate resmetirom, targeting a liver condition called NASH. The NASH market is projected to reach $50 billion by 2035, ...
Madrigal Pharmaceuticals secures global rights to SYH2086, aiming to enhance MASH treatment with innovative combination therapies for better patient outcomes. The exclusive global agreement will allow ...
Madrigal Pharmaceuticals' Rezdiffra generated sales of $287 million in the third quarter for a 35% sequential jump from Q2. In just its fifth full quarter on the market, the world’s first treatment ...
In the 1970s, doctors sterilized Dolores Madrigal without her knowledge. She became the lead plaintiff in a lawsuit by Mexican-American women who said they were coerced into having their tubes tied. A ...
A woman at the center of a landmark lawsuit on reproductive rights has died. Dolores Madrigal was 39 years old in the early 1970s when she was sterilized by the doctors who had just delivered her baby ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback